NQO1 and neoplasm: Although this phase 1 trial suggests that tumours with high expression of NQO1 by IHC may be associated with clinical benefit of ARQ 761 and other β-lap analogues, from this relatively small sample it is not clear that this assay or the selected cut point (H-score 200) represents the optimal enrollment biomarker for β-lap trials.